BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has successfully closed the second part of its funding efforts, securing $138,117 through the sale of over 2.7 million units and settling $40,000 in debt with shares. The capital will enhance the company’s working budget, facilitating the advancement of its acquired immunological and biotech assets, including the DPX™ platform technology for various medical fields.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
